HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.

2nd Edition of International Conference

and Expo on Clinical Microbiology

June 23-24, 2023 | Rome, Italy

ICCM 2022

Miguel Cruz

Speaker at Clinical Microbiology 2022 - Miguel Cruz
Mexican Social Security Institute., Mexico
Title : Gut microbiome is associated with obesity, fasting plasma insulin and serum enzymatic activity of amylase in Mexican children


Background.  The last national survey of health and nutrition in Mexico (2020) reported a prevalence of obesity of 18.6% and 17.0% in children and adolescents, respectively. Although recently, we evidenced a negative association of serum enzymatic activity of salivary (AMY1) and pancreatic (AMY2) amylase with obesity risk in children eating medium/high amount of starch, little is known about the relationship between obesity, serum AMY1 and AMY2 enzymatic activity, and gut microbiota. 
Objective. We analyzed the association between obesity, serum AMY1/AMY2 enzymatic activity and gut microbiota in up to 92 and 78 Mexican children with normal weight (NW) and with obesity (OB).
 Methods. Anthropometric data and serum AMY1/AMY2 measurements were analyzed. Composition of microbial communities was determined by high-throughput sequencing of the V3-V4 regions of bacterial 16S rRNA genes.
Results. The gut microbial community structure was associated with obesity and fasting plasma insulin (FPI) (POB=0.012, PFPI=0.0003). Gut microbiata was also associated with serum enzymatic activity of AMY2 in children with NW (PNW= 0.003) and OB (POB= 0.027) by separate. While obesity was positively associated with Fusicatenibacter (p= 0.017) and Romboutsia (p= 0.017), FPI was negatively associated with Blautia (p= 0.013). Additionally, a significant interaction was found between AMY2 and obesity status (p<0.05). There is a positive association between the highest tertile of AMY2 enzyme activity and alpha diversity (observed richness, Shannon diversity and Inverse Simpson index) in children with obesity (p<0.05). In children with NW and OB, tertiles of AMY2 were positively associated with one Akkermansia ASV (p≤ 1.2x10-7) and one Ruminococcaceae_UCG-014 ASV (p≤ 5.8x10-9).
Conclusion.  Our results confirm that gut microbial community is associated with childhood obesity and FPI. For our knowledge, this is the first report regard the serum AMY2 enzymatic activity is associated with the relative abundance of Akkermansia and Ruminococcaceae_UCG-014 (oligosaccharide-fermenting and SCFA-producing bacteria).  

What will audience learn from your presentation? 
•    Our results show an epidemiologic case of association between gut microbiota, obesity and serum enzymatic activity of amylase. 
•    The main objective of the global project is to accumulate evidence to support the use of serum enzymatic activity of amylase as a potential biomarker of obesity and its metabolic complications.
•    In the future, we expect that serum enzymatic activity of amylase play an important role into the treatment and / or prevention of obesity and its metabolic complications, through the design of personalized prescriptions of diets.



He is a National Investigator Level 3 and Head of the Unidad de Investigación Médica en Bioquímica of the Instituto Mexicano del Seguro Social, in Mexico. Active member of the Academia Nacional de Medicina de Mexico, and since 2017 is Co-editor of the Gaceta Médica de México journal. Member of the Global Lipids Genetics Consortium. He is author of 3 books, 20 book chapiters, 198 journal articles, and to date he has 4,215 citations. In the biomedical science, he has graduated 39 bachelors, 23 masters, 11 PhD´s, and 14 medical specialty students.